Medicinal Chemistry Journal of Medicinal Chemistry

Macrocyclic sulfonamides switch on SIRT3 to protect failing hearts

  • A modular, biomimetic design built macrocyclic sulfonamides, and SAR work identified lead 2b (Y0855).
  • 2b activates SIRT3 while sparing SIRT1, SIRT2 and SIRT6, addressing the weak potency and poor selectivity of earlier activators.
  • In cardiomyocytes it eased oxidative stress, injury and fibrosis via SIRT3; in doxorubicin-induced mice it restored cardiac function.
  • Better metabolic stability makes it a useful lead starting point.
Points Based on the abstract

Sirtuin activators have a history of assay artifacts, so how 2b was validated matters: is activation substrate-dependent, and does it hold with native, label-free peptides? Without a co-crystal or HDX map the binding site is a guess and the macrocycle SAR can't be rationalized. Direct engagement (CETSA, SIRT3 knockout cells) and a check for off-target mitochondrial effects would firm it up.